Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- Technical specifications for submitting clinical trial data sets for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH)2
- A risk-based approach to monitoring of clinical investigations questions and answers: guidance for industry1
- Advancing treatment, providing options: à l'avant-garde de la recherche thérapeutique1
- An address delivered before the Rhode-Island Homoeopathic Society1
- An evidence-based health care system: the case for clinical trials registries : Office of Medical Applications of Research, National Institutes of Health [and] National Library of Medicine, Lister Hill Auditorium, Bethesda, Maryland, December 6-7, 19931
- Anthrax: developing drugs for prophylaxis of inhalational anthrax1
- Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff1
- Area V Minute News1
- Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment1
- Bacterial vaginosis: developing drugs for treatment1
- Bioavailability studies submitted in NDAs or INDs: general considerations1
- Cancer clinical trial eligibility criteria: available therapy in non-curative settings1
- Cancer clinical trial eligibility criteria: brain metastases1
- Cancer clinical trial eligibility criteria: minimum age considerations for inclusion of pediatric patients : guidance for industry and IRBs1
- Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B Virus, or hepatitis C Virus Infections1
- Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies1
- Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment1
- Civil money penalties relating to the ClinicalTrials.gov data bank: guidance for responsible parties, submitters of certain applications and submissions to FDA, and FDA staff1
- Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions1
- Clinical trials supported by the National Eye Institute: evaluating new approaches to the treatment of eye and vision disorders1